Nova Eye Medical (AU:EYE)
ASX:EYE
EYE Stock Chart & Stats
AU$0.13
-AU$0.01(-5.26%)
At close: 4:00 PM EST
AU$0.13
-AU$0.01(-5.26%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.21
Previous CloseN/A
Volume155.74K
Average Volume (3M)204.72K
Market Cap
AU$35.61M
Enterprise ValueAU$37.92M
Total Cash (Recent Filing)AU$2.62M
Total Debt (Recent Filing)AU$4.94M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding284,840,270
10 Day Avg. Volume176,528
30 Day Avg. Volume204,722
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)1.43
Price to Sales (P/S)0.93
P/FCF Ratio-4.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$35.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth indicates expanding adoption of the company's ophthalmic products and services. Durable top-line expansion over multiple quarters supports continued market penetration and provides a base to scale gross profits and operating leverage if cost trends stabilize.
Low Leverage / Balance Sheet StabilityA low debt-to-equity ratio gives the company financial flexibility to fund product development, capital equipment, or bridge shortfalls without immediate refinancing pressure. This reduces insolvency risk and supports investment choices over the next several quarters.
Consumables-driven Business MixA product mix that includes surgical consumables creates recurring revenue streams and customer stickiness from repeat purchases. Durable consumables demand from clinical procedures supports more predictable unit volumes and a stronger lifetime customer value profile.
Bears Say
Negative Operating & Free Cash FlowSustained negative operating and free cash flow undermines the firm's ability to self-fund growth and operations. Over a multi-quarter horizon this necessitates external financing, which can dilute equity or increase leverage, constraining strategic flexibility.
Ongoing UnprofitabilityPersistent negative net profit and EBIT margins indicate the company has not yet demonstrated scalable profitability. Continued losses erode retained earnings and limit reinvestment capacity, making long-term margin recovery and sustainable returns uncertain.
Material Gross Margin DeclineA sharp decline in gross margin suggests rising manufacturing costs or pricing pressure on core products. If structural, this reduces the safety margin for operating expenses and delays path to profitability, pressuring margins even if revenue growth continues.
Nova Eye Medical News
EYE FAQ
What was Nova Eye Medical’s price range in the past 12 months?
Nova Eye Medical lowest share price was AU$0.09 and its highest was AU$0.20 in the past 12 months.
What is Nova Eye Medical’s market cap?
Nova Eye Medical’s market cap is AU$35.61M.
When is Nova Eye Medical’s upcoming earnings report date?
Nova Eye Medical’s upcoming earnings report date is Aug 27, 2026 which is in 147 days.
How were Nova Eye Medical’s earnings last quarter?
Nova Eye Medical released its earnings results on Feb 25, 2026. The company reported -AU$0.012 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.007.
Is Nova Eye Medical overvalued?
According to Wall Street analysts Nova Eye Medical’s price is currently Overvalued.
Does Nova Eye Medical pay dividends?
Nova Eye Medical pays a Weekly dividend of AU$0.414 which represents an annual dividend yield of N/A. See more information on Nova Eye Medical dividends here
What is Nova Eye Medical’s EPS estimate?
Nova Eye Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nova Eye Medical have?
Nova Eye Medical has 284,840,270 shares outstanding.
What happened to Nova Eye Medical’s price movement after its last earnings report?
Nova Eye Medical reported an EPS of -AU$0.012 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Nova Eye Medical?
Currently, no hedge funds are holding shares in AU:EYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nova Eye Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:EYE Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $7.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-44.16%
Trailing 12-Months
Asset Growth
-12.96%
Trailing 12-Months
Company Description
Nova Eye Medical
Nova Eye Medical Limited designs, develops, distributes, markets, sells, and services surgical devices for the treatment of glaucoma. The company offers iTrack, a surgical system for the reduction in intraocular pressure (IOP) in adult patients with open-angle glaucoma; iTrack Advance, a natural ocular drainage system; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Asia Pacific, and internationally. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was founded in 1985 and is headquartered in Kent Town, Australia.
Technical Analysis
Compumedics Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―
Options Prices
Currently, No data available
---